The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

The efficacy and safety of upadacitinib — a selective Janus kinase (JAK) inhibitor that blocks the signaling of several cytokines, including interleukin-6 and interferon-γ — are unknown in ...

No association was observed between serious infection risk and Janus kinase inhibitor use in patients with immune-mediated inflammatory skin disease.

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies. Ruxolitinib ...

“[This study] proves that oral Janus kinase inhibitors work well by themselves for vitiligo, but there is an added benefit to nbUVB,” Guttman-Yassky said. “If you want the best ...

Janus kinase (JAK) inhibitors were associated with more infections, particularly herpes infections, in patients with atopic dermatitis (AD) compared with biologics, in a cohort study. A ...

50% of Patients Previously Exposed to Biologics or Janus kinase inhibitor (JAKi) About 50% of the 165 patients enrolled in the OLE study had received biologics or non-TYK2 JAKis previously.